HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating [Yahoo! Finance]
Alumis Inc. (ALMS)
Company Research
Source: Yahoo! Finance
The adjustment came after the company shared promising results earlier in the week from the Phase 3 ONWARD1 and ONWARD2 trials evaluating the efficacy of envudeucitinib in patients with moderate to severe plaque psoriasis. Both trials achieved their primary and secondary endpoints. Moreover, the results demonstrated safe usage and tolerability among patients, who also reported a significant improvement in their quality of life through eased itching. Alumis Inc. is planning to file for the drug's approval with the FDA during the latter half of 2026. HC Wainwright & Co. believes the results have ‘reset expectations' in the area of oral tyrosine kinase 2 (TYK2). The firm sees a strong chance of the FDA approving envudeucitinib, which could lead to a major revenue surge for the company. Several other research firms, including Wells Fargo and Morgan Stanley, also revised their positions on the stock following the announcement of trial results by increasing their price targets on Alu
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Alumis Announces Pricing of Upsized Public Offering of Common StockGlobeNewswire
- Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise [Seeking Alpha]Seeking Alpha
- Alumis (NASDAQ:ALMS) had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
ALMS
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form SCHEDULE
- 1/12/26 - Form 4
- ALMS's page on the SEC website